We have recently reported that among 163 BRCA-negative triple-negative breast cancer patients in Cyprus, 4.3% are positive for PVs in PALB2 (Zanti et al., 2020), whereas PALB2 PVs consisted 87.5% of the PVs detected using a panel of 94 cancer susceptibility genes. This evidence concerns the gene PALB2 and cancer.